Schedule of Segment Reporting Information, by Segment |
The following table summarizes segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands): | | | | | | | | | | | | | | | | | | | 2021 | | 2020 | | 2019 | Net revenue: | | | | | | Clinical Services | $ | 404,172 | | | $ | 382,337 | | | $ | 361,161 | | Pharma Services | 80,157 | | | 62,111 | | | 47,669 | | Total net revenue | 484,329 | | | 444,448 | | | 408,830 | | | | | | | | Cost of revenue: | | | | | | Clinical Services(1) | 244,360 | | | 215,529 | | | 185,612 | | Pharma Services(2) | 52,909 | | | 43,026 | | | 26,382 | | Total cost of revenue | 297,269 | | | 258,555 | | | 211,994 | | | | | | | | Gross profit: | | | | | | Clinical Services | 159,812 | | | 166,808 | | | 175,549 | | Pharma Services | 27,248 | | | 19,085 | | | 21,287 | | Total gross profit | 187,060 | | | 185,893 | | | 196,836 | | | | | | | | Operating expenses: | | | | | | General and administrative | 221,347 | | | 143,794 | | | 127,993 | | Research and development | 21,873 | | | 8,229 | | | 8,487 | | Sales and marketing | 62,594 | | | 47,862 | | | 47,350 | | Total operating expenses | 305,814 | | | 199,885 | | | 183,830 | | (Loss) income from operations | (118,754) | | | (13,992) | | | 13,006 | | Interest expense, net | 5,082 | | | 7,019 | | | 3,713 | | Other expense (income), net | 499 | | | (7,906) | | | 4,630 | | Gain on investment in and loan receivable from non-consolidated affiliate, net | (109,260) | | | (3,955) | | | — | | Loss on extinguishment of debt | — | | | 1,400 | | | 1,018 | | Loss on termination of cash flow hedge | — | | | 3,506 | | | — | | (Loss) income before taxes | (15,075) | | | (14,056) | | | 3,645 | | Income tax benefit | (6,728) | | | (18,228) | | | (4,361) | | Net (loss) income | $ | (8,347) | | | $ | 4,172 | | | $ | 8,006 | |
(1) Clinical Services cost of revenue in 2021 includes $9.2 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory. (2) Pharma Services cost of revenue in 2021 includes $1.2 million of amortization of acquired Inivata developed technology intangible assets.
|